Last updated: 2026-09-09 04:54:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
PROCEPT BioRobotics Corporation (PRCT) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $21,33, with a market capitalisation of $1,30B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16,67 to $41,51. This page covers its latest market performance, valuation, price trends and company information.
$1,30B | |
$22,49 | |
$103,81 | |
$15,38 | |
$22,76 | |
1,40M | |
1,59M | |
-- | |
$41,51 | |
$16,67 | |
-- | |
-- |
PROCEPT BioRobotics Corporation (PRCT) last closed at $22,76 as of 2026-09-08 23:54:00, unchanged from the previous close of $22,76.
During the latest regular trading session, PRCT traded between $15,38 and $103,81, with a volume of 1,40M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, PROCEPT BioRobotics Corporation (PRCT) moved from $20,60 to $21,33, representing a gain of 3,54% ($0,73).
The stock traded between $20,33 and $22,84 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1,03 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 18,8%
PRCT is currently trading at $21,33, placing it 18,8% of the way from its 52-week low of $16,67 to its 52-week high of $41,51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 888 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PROCEPT BioRobotics Corporation (PRCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.